J
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Price:
19.7
CNY
-0.56%
Market Closed
Market Cap:
¥2.4B
Relative Value
The Relative Value of one Jiangsu GDK Biotechnology Co Ltd stock under the Base Case scenario is 13.04 CNY. Compared to the current market price of 19.7 CNY, Jiangsu GDK Biotechnology Co Ltd is Overvalued by 34%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
13.04
CNY
Overvaluation 34%
J
Multiples Across Competitors
Competitors Multiples
Jiangsu GDK Biotechnology Co Ltd Competitors
Jiangsu GDK Biotechnology Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
J
|
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
|
2.4B CNY | 20.8 | -19.2 | -13.9 | -13.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.8B USD | 6.6 | 168.6 | 16.3 | 23.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.7B USD | 5.5 | 26.3 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188B USD | 6.4 | 22.1 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119B USD | 9.9 | 30.1 | 23 | 24 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD | 5.8 | 18.3 | 13.9 | 15.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
73.4B AUD | 3.3 | 17.2 | 11.8 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR | 14.5 | 34 | 58.5 | 60.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
